Kymera Therapeutics
KYMR
210 hedge funds and large institutions have $4.58B invested in Kymera Therapeutics in 2025 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 81 increasing their positions, 54 reducing their positions, and 38 closing their positions.
167% more call options, than puts
Call options by funds: $8.81M | Put options by funds: $3.3M
50% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 54
33% more capital invested
Capital invested by funds: $3.44B → $4.58B (+$1.14B)
5% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 38
0% more funds holding
Funds holding: 210 → 210 (0)
8% less funds holding in top 10
Funds holding in top 10: 13 → 12 (-1)
7.91% less ownership
Funds ownership: 121.01% → 113.1% (-7.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Holocene Advisors
New York
|
+$37.9M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$25.5M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$25.2M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$23.5M |
| 5 |
State Street
Boston,
Massachusetts
|
+$21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$79.5M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$35.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$21.5M |
| 4 |
SCM
Suvretta Capital Management
New York
|
-$12M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$11.3M |
KYMR Hedge Fund Activity: Q3 2025 in Review
210 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q3 2025, worth a combined $4.58B — up 33% from $3.44B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new KYMR positions and 38 closed out — a net gain of 2 holders — while 81 added to existing stakes and 54 trimmed.
The largest buyer was Holocene Advisors, opening a new position worth an estimated $37.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $79.5M.
- 210 institutional investors held Kymera Therapeutics (KYMR) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $4.58B of Kymera Therapeutics stock for Q3 2025, up 33% quarter-over-quarter.
- 40 funds opened new Kymera Therapeutics positions in Q3 2025 and 38 closed out, a net change of +2 holders.
- The largest Kymera Therapeutics buyer in Q3 2025 was Holocene Advisors, an estimated $37.9M added.
- The largest Kymera Therapeutics seller in Q3 2025 was T. Rowe Price Associates, an estimated $79.5M sold.
Based on aggregated 13F filings for Q3 2025.